Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia

Objective:The authors assessed the efficacy, safety, and tolerability of MIN-101, a compound with affinities for sigma-2 and 5-HT2A receptors and no direct dopamine affinities, in comparison with placebo in treating negative symptoms in stabilized patients with schizophrenia.Method:The trial enrolle...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The American journal of psychiatry 2017-12, Vol.174 (12), p.1195-1202
Hauptverfasser:	Davidson, Michael, Saoud, Jay, Staner, Corinne, Noel, Nadine, Luthringer, Elisabeth, Werner, Sandra, Reilly, Joseph, Schaffhauser, Jean-Yves, Rabinowitz, Jonathan, Weiser, Mark, Luthringer, Remy
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Antipsychotic Agents - therapeutic use Antipsychotics Clinical significance Clinical trials Double-Blind Method Double-blind studies Female Humans Indoles - adverse effects Indoles - therapeutic use Male Middle Aged Placebo effect Prescription drugs Psychiatric Status Rating Scales Safety Schizophrenia Schizophrenia - drug therapy Schizophrenic Psychology Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!